Literature DB >> 10678496

Oestrogenic compounds modulate cytokine-induced nitric oxide production in mouse osteoblast-like cells.

R L van Bezooijen1, C Van der Bent, S E Papapoulos, C W Löwik.   

Abstract

Nitric oxide (NO) is a mediator of bone metabolism with effects on both bone resorption and formation. Its production by both the constitutive and inducible isoforms of nitric oxide synthase (NOS) is affected by oestrogen in several types of cell and in tissues other than bone cells. Recently, oestrogens were found to increase basal NO production by osteoblasts via enhanced activity or expression, or both, of NOS-3. Inflammatory cytokines, however, increase NO by increasing the expression of NOS-2. In this study we have examined whether cytokine-induced NO production by osteoblastic cells was affected by oestrogenic compounds by studying the effect of 17beta-oestradiol and the anti-oestrogens ICI164,384 and 4-hydroxytamoxifen on cytokine-induced NO production in oestrogen receptor positive MC3T3-E1 osteoblast-like cells. Combinations of the inflammatory cytokines interleukin-1beta, tumour necrosis factor-alpha, and interferon-gamma with lipopolysaccharide stimulated NO production up to 11-fold. This cytokine-induced NO production was further increased dose-dependently by the anti-oestrogens ICI164,384 and 4-hydroxytamoxifen (133.3 +/- 3.2% and 146.0 +/- 13.2%, respectively). 17Beta-oestradiol either had no effect on or slightly inhibited cytokine-induced NO production. It did, however, dose-dependently counteract the stimulatory effect of the anti-oestrogens. Concentrations of 17beta-oestradiol needed to prevent the stimulatory effect of 4-hydroxytamoxifen were ca tenfold that of ICI164,384. These findings show that, in addition to the stimulatory effect of oestrogen on basal NO production by NOS-3, cytokine-induced NO production is also affected by oestrogenic compounds in osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10678496     DOI: 10.1211/0022357991777047

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  Increased In Vitro Osteopotential in SHED Associated with Higher IGF2 Expression When Compared with hASCs.

Authors:  Roberto Dalto Fanganiello; Felipe Augusto Andre Ishiy; Gerson Shigeru Kobayashi; Lucas Alvizi; Daniele Yumi Sunaga; Maria Rita Passos-Bueno
Journal:  Stem Cell Rev Rep       Date:  2015-08       Impact factor: 5.739

2.  Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.

Authors:  U Coskun; N Gunel; B Sancak; E Onuk; M Bayram; A Cihan
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.